Anthony O. Caggiano

Multi-omics comparative analyses of synucleinopathy models reveal distinct drug targets and relevance for drug development

The set of disrupted proteins/genes were compared to that aberrantly expressed in human PD and dementia with Lewy bodies and candidate drug targets in a “PD drug development pipeline”, revealing potential disease biomarkers and optimal models for testing novel therapeutics.